Valeant Pharma (VRX) Sees Solid Upside

November 11, 2016 10:41 AM EST

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Valeant Pharma (NYSE: VRX) is seeing solid upside Friday. Shares are up 4.4%. Upside comes in part as large shareholder and Director, Bill Ackman, discussed the stock at length yesterday and suggested the company may have to change its name amid all the scrutiny it has insured. Also, shares continue to benefit as a Trump presidency is seen better for drug prices. Shares are up 16% since Trump was elected.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Trader Talk

Related Entities

William Ackman

Add Your Comment